HILPDA-AS1: A Potential Drug Target and Biomarker (G102724660)

Target Name: HILPDA-AS1

NCBI ID: G102724660

HILPDA-AS1

Other Name(s): HILPDA antisense RNA 1, transcript variant X2 | HILPDA antisense RNA 1

HILPDA-AS1: A Potential Drug Target and Biomarker

HILPDA-AS1, also known as HILPDA antisense RNA 1, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the immune response and has been shown to play a critical role in the regulation of inflammation and autoimmune diseases.

HILPDA-AS1 is a member of the HILPDA gene family, which is known for its ability to regulate the expression of genes in response to stress and inflammation. The HILPDA gene family has been shown to play a role in the regulation of a wide range of physiological processes, including immune response, stress resistance, and cell survival.

HILPDA-AS1 is a short non-coding RNA molecule that consists of 19 amino acid residues. It is expressed in a variety of tissues and cells, including immune cells, tissues, and organs. HILPDA-AS1 has been shown to play a critical role in the regulation of the immune response, and it has been shown to play a role in the development and progression of a variety of autoimmune diseases.

One of the key functions of HILPDA-AS1 is its ability to regulate the expression of genes that are involved in the immune response. It has been shown to interact with a wide range of immune cell surface molecules, including T cells, B cells, and dendritic cells. HILPDA-AS1 has also been shown to play a role in the regulation of the production of antibodies, as well as the regulation of inflammation.

Another function of HILPDA-AS1 is its ability to act as a negative regulator of the NF-kappa-B signaling pathway. NF-kappa-B is a protein that is involved in the regulation of a wide range of cellular processes, including inflammation, cell survival, and cell proliferation. HILPDA-AS1 has been shown to play a role in the regulation of the NF-kappa-B signaling pathway, and it has been shown to act as an inhibitor of the pathway.

HILPDA-AS1 has also been shown to play a role in the regulation of cell apoptosis, or cell death. It has been shown to interact with the protein Bax, which is involved in the regulation of cell apoptosis. HILPDA-AS1 has been shown to play a role in the regulation of Bax expression and has been shown to act as a potential inhibitor of Bax function.

In addition to its role in the regulation of the immune response and cell apoptosis, HILPDA-AS1 has also been shown to play a role in the regulation of inflammation. It has been shown to interact with the protein NF-kappa-B, as mentioned earlier, and has been shown to play a role in the regulation of the production of pro-inflammatory cytokines.

Given its wide range of functions and its ability to interact with a wide range of molecules, HILPDA-AS1 is a promising candidate for drug targeting. Studies have shown that HILPDA-AS1 can be effectively targeted with small molecules, and several compounds have been shown to be able to inhibit HILPDA-AS1 function. These compounds have been shown to have a wide range of therapeutic potential, including the treatment of a variety of autoimmune diseases, including rheumatoid arthritis, lupus, and multiple sclerosis.

In addition to its potential as a drug target, HILPDA-AS1 is also a promising biomarker for a variety of diseases. Studies have shown that HILPDA-AS1 is often expressed at higher levels in individuals with autoimmune diseases, and that it is involved in the regulation of the immune response. As a result, HILPDA-AS1 has been suggested as a potential biomarker for a variety of autoimmune diseases, including

Protein Name: HILPDA Antisense RNA 1

The "HILPDA-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HILPDA-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets